Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ

21.34

-0.37(-1.70%)

Updated at March 13 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Emil D. Kakkis	Founder, President, Chief Executive Officer & Director	1.63M	1960
Dennis Karl Huang	Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations	331,330	1965
Karah Herdman Parschauer	Chief Legal Officer & Executive Vice President of Corporate Affairs	846,744	1978
John Richard Pinion	Chief Quality Operations Officer & Executive Vice President of Translational Sciences	923,934	1966
Howard Horn	Executive Vice President of Corporate Strategy & Chief Financial Officer	947,770	1979
Erik Harris	Executive VP & Chief Commercial Officer	985,266	1970
Eric Crombez	Chief Medical Officer & Executive VP	987,676	1973
Ernie W. Meyer	Chief Human Resources Officer & Executive Vice President	0	1965
Theodore A. Huizenga	Senior Vice President, Corporate Controller & Principal Accounting Officer	0	1971
Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	0	1965

Name

Title

Pay

Year Born

Emil D. Kakkis

Founder, President, Chief Executive Officer & Director

1.63M

1960

Dennis Karl Huang

Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations

331,330

1965

Karah Herdman Parschauer

Chief Legal Officer & Executive Vice President of Corporate Affairs

846,744

1978

John Richard Pinion

Chief Quality Operations Officer & Executive Vice President of Translational Sciences

923,934

1966

Howard Horn

Executive Vice President of Corporate Strategy & Chief Financial Officer

947,770

1979

Erik Harris

Executive VP & Chief Commercial Officer

985,266

1970

Eric Crombez

Chief Medical Officer & Executive VP

987,676

1973

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

1965

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

1971

Vimal Srivastava

Senior Vice President of Business Development & Alliance Management

1965

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.